Literature DB >> 12887649

Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E.

Sergio Rosales-Corral1, Dun-Xian Tan, Russel J Reiter, Miguel Valdivia-Velázquez, Gabriela Martínez-Barboza, J Pablo Acosta-Martínez, Genaro G Ortiz.   

Abstract

To determine the efficacy of antioxidants in reducing amyloid-beta-induced oxidative stress, and the neuroinflammatory response in the central nervous system (CNS) in vivo, three injections of fibrillar amyloid-beta (fAbeta) or artificial cerebrospinal fluid (aCSF) into the CA1 region of the hippocampus of the rat were made. Concomitantly, one of the three free radical scavengers, i.e. melatonin, vitamin C, or vitamin E was also administered. Besides being a free radical scavenger, melatonin also has immunomodulatory functions. Antioxidant treatment reduced significantly oxidative stress and pro-inflammatory cytokines. There were no marked differences between melatonin, vitamin C, and vitamin E regarding their capacity to reduce nitrites and lipoperoxides. However, melatonin exhibited a superior capacity to reduce the pro-inflammatory response induced by fAbeta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12887649     DOI: 10.1034/j.1600-079x.2003.00057.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  37 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Melatonin and nitric oxide: two required antagonists for mitochondrial homeostasis.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Luis C López; Ana B Hitos; Josefa León
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 3.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 4.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

Review 5.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

Authors:  Wen-Ying Wang; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-06

6.  Influence of melatonin on cerebrovascular proinflammatory mediators expression and oxidative stress following subarachnoid hemorrhage in rabbits.

Authors:  Qi Fang; Gang Chen; Weiwei Zhu; Wanli Dong; Zhong Wang
Journal:  Mediators Inflamm       Date:  2010-01-31       Impact factor: 4.711

7.  Comparative effects of melatonin and vitamin E in restoring aortic relaxation in pancreatectomized rats.

Authors:  C F Reyes-Toso; L M Linares; L E Albornoz; D Obaya-Naredo; M L Wallinger; C R Ricci; D P Cardinali
Journal:  J Physiol Biochem       Date:  2006-09       Impact factor: 4.158

Review 8.  Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.

Authors:  Lynn Marie Trotti; Elias G Karroum
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 9.  Melatonin: an established antioxidant worthy of use in clinical trials.

Authors:  Ahmet Korkmaz; Russel J Reiter; Turgut Topal; Lucien C Manchester; Sukru Oter; Dun-Xian Tan
Journal:  Mol Med       Date:  2008-11-04       Impact factor: 6.354

Review 10.  Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.

Authors:  Morgana Moretti; Daiane Bittencourt Fraga; Ana Lúcia S Rodrigues
Journal:  CNS Neurosci Ther       Date:  2017-10-04       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.